DebKCardsPA, you ask about a buyout.  RVX has two major stockholders, Eastern Capital Limited and Shenzhen Hepalink along with many employees.  We should be thanking each for their sustained support.  I do not see SH letting the company go.  And I do not see SH acquiring the majority (control) of the Company.  Too much political turmoil between US and China.  SH paid $8 MM for the first right to be the major supplier.  An agreement still must be reached between RVX and manufacture-seller.  Royalties to RVX should be in the 10% to 12% gross wholesale range.  China has the largest percentage of their popultion with Type II diabetes. With full patient enrollment, there should be about 8 billion oral doses manufactured annually.  Not a small number.

When does this happen? Does any one know?  With positive announcement on Nov 16, RVX still must submitt a request for approval.  Will take time.  In May of 2018, FDA stated if Phase III is favorable, they will grant a license.  Not sure, hopefully this means a fast track.

Does any one know if Lipitor was used in the Australia Phase IIb study.  I do not recall.  After the six month study, the results were off the chart.  We were all waiting for the same result. It appears combining Lipitor with RVX is detrimental to our health.

I could be misinformed, please correct.  If all goes well Nov 16th, looking for approval early 2021.